David S Goldberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3096815/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVIDâ€19 Pandemic: A National Cohort Study. Hepatology Communications, 2022, 6, 3186-3193.	2.0	4
2	Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori. Digestive Diseases and Sciences, 2022, 67, 1822-1830.	1.1	5
3	Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e1121-e1134.	2.4	12
4	Best Practices in Large Database Clinical Epidemiology Research in Hepatology: Barriers and Opportunities. Liver Transplantation, 2022, 28, 113-122.	1.3	3
5	Acuteâ€onâ€Chronic Liver Failure and Liver Transplantation: Putting the Cart Before the Horse in Data Analyses and Advocating for Model for Endâ€Stage Liver Disease Exceptions. Liver Transplantation, 2022, 28, 535-538.	1.3	8
6	Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. Journal of Hepatology, 2022, 76, 75-85.	1.8	22
7	Procurement characteristics of high- and low-performing OPOs as seen in OPTN/SRTR data. American Journal of Transplantation, 2022, 22, 455-463.	2.6	10
8	Impact of Raceâ€Adjusted Glomerular Filtration Rate Estimation on Eligibility for Simultaneous Liverâ€Kidney Transplantation. Liver Transplantation, 2022, 28, 959-968.	1.3	7
9	Impact of Medicaid Expansion on Liver-Related Mortality. Clinical Gastroenterology and Hepatology, 2022, 20, 419-426.e1.	2.4	17
10	Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. Transplantation, 2022, 106, 72-84.	0.5	8
11	Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. American Journal of Transplantation, 2022, 22, 599-609.	2.6	12
12	Use of Livers With Fibrosis Based on Donor Hospital Biopsy: Missed Opportunities?. Liver Transplantation, 2022, 28, 717-721.	1.3	3
13	External Validation of the FIPS Score for Post-TIPS Mortality in a National Veterans Affairs Cohort. Digestive Diseases and Sciences, 2022, 67, 4581-4589.	1.1	9
14	Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal of Hepatology, 2022, 76, 1100-1108.	1.8	22
15	Effect of Acuity Circles Allocation Policy on Local Use of Donation After Circulatory Death Donor Livers. Liver Transplantation, 2022, 28, 1103-1107.	1.3	6
16	Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database. Journal of Hepatology, 2022, 76, 1122-1126.	1.8	10
17	Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis. Digestive Diseases and Sciences, 2022, 67, 4395-4402.	1.1	4
18	Trends in the Incidence of Upper Gastrointestinal Cancers Show Changing Dynamics. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	1

#	Article	IF	CITATIONS
19	Accurate longâ€ŧerm prediction of death for patients with cirrhosis. Hepatology, 2022, 76, 700-711.	3.6	5
20	Factors Associated With Geographic Disparities in Gastrointestinal Cancer Mortality in the United States. Gastroenterology, 2022, 163, 437-448.e1.	0.6	16
21	Lost potential and missed opportunities for DCD liver transplantation in the United States. American Journal of Surgery, 2022, 224, 990-998.	0.9	2
22	Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States. Liver Transplantation, 2022, 28, 1857-1864.	1.3	11
23	County-level Differences in Liver-related Mortality, Waitlisting, and Liver Transplantation in the United States. Transplantation, 2022, 106, 1799-1806.	0.5	1
24	Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes. Transplantation, 2022, 106, 2182-2192.	0.5	3
25	Center-level and region-level variations in liver transplantation practices following acuity circles policy change. American Journal of Transplantation, 2022, 22, 2668-2674.	2.6	7
26	Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration. Clinical Gastroenterology and Hepatology, 2021, 19, 305-313.e1.	2.4	17
27	Donor derived hepatitis B virus infection: Analysis of the Organ Procurement & Transplantation Network/United Network for Organ Sharing <i>Ad Hoc</i> Disease Transmission Advisory Committee. Transplant Infectious Disease, 2021, 23, e13458.	0.7	8
28	Preface. Clinics in Liver Disease, 2021, 25, xiii-xiv.	1.0	0
29	County Differences in Liver Mortality in the United States: Impact of Sociodemographics, Disease Risk Factors, and Access to Care. Gastroenterology, 2021, 160, 1140-1150.e1.	0.6	20
30	Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. Liver Transplantation, 2021, 27, 699-710.	1.3	11
31	State Medicaid Restrictions for Directâ€Acting Antiviral Therapy Do Not Impact Posttransplant Outcomes of Recipients of Hepatitis C Virus–Viremic Livers. Liver Transplantation, 2021, 27, 140-143.	1.3	1
32	A 6â€Month Report on the Impact of the Organ Procurement and Transplantation Network/United Network for Organ Sharing Acuity Circles Policy Change. Liver Transplantation, 2021, 27, 756-759.	1.3	31
33	Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. Annals of Surgical Oncology, 2021, 28, 1929-1936.	0.7	7
34	Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acuteâ€onâ€Chronic Liver Failure. Liver Transplantation, 2021, 27, 16-26.	1.3	20
35	Risk Prediction Models for Postâ€Operative Mortality in Patients With Cirrhosis. Hepatology, 2021, 73, 204-218.	3.6	83
36	Acute-on-chronic liver failure: update on pathogenesis, therapeutic targets, predictive models, and liver transplantation. Current Opinion in Gastroenterology, 2021, 37, 173-178.	1.0	6

#	Article	IF	CITATIONS
37	Male Sex Is Associated With Higher Rates of Liverâ€Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology, 2021, 74, 879-891.	3.6	36
38	Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. American Journal of Gastroenterology, 2021, 116, 1913-1923.	0.2	28
39	Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. Gastroenterology, 2021, 160, 2162-2164.e3.	0.6	17
40	Validating a novel algorithm to identify patients with autoimmune hepatitis in an administrative database. Pharmacoepidemiology and Drug Safety, 2021, 30, 1168-1174.	0.9	4
41	Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. Hpb, 2021, 23, 868-876.	0.1	7
42	Development and Validation of a Model to Predict Longâ€Term Survival After Liver Transplantation. Liver Transplantation, 2021, 27, 797-807.	1.3	10
43	Disentangling the obesity paradox in upper gastrointestinal cancers: Weight loss matters more than body mass index. Cancer Epidemiology, 2021, 72, 101912.	0.8	4
44	Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. Journal of Hepatology, 2021, 74, 1398-1406.	1.8	23
45	Race, Education, and Gender Disparities in Transplantation of Kidneys From Hepatitis C Viremic Donors. Transplantation, 2021, 105, 1850-1857.	0.5	9
46	A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients. Kidney International, 2021, 100, 1190-1198.	2.6	12
47	External Validation of the VOCALâ€Penn Cirrhosis Surgical Risk Score in 2 Large, Independent Health Systems. Liver Transplantation, 2021, 27, 961-970.	1.3	17
48	Changes in County-Level Economic Prosperity Are Associated With Liver Disease–Related Mortality Among Working-Age Adults. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	1
49	Protecting Patients With Cirrhosis From Coronavirus Disease 2019: Identifying Gaps in Vaccination Rates. Liver Transplantation, 2021, 27, 1535-1537.	1.3	0
50	Evaluating the impact of frailty on periprocedural adverse events and mortality among patients with GI bleeding. Gastrointestinal Endoscopy, 2021, 94, 517-525.e11.	0.5	15
51	Medicaid Expansion and Enhanced Coverage of Direct Oral Antivirals: Improving Care for Patients With Liver Disease. Liver Transplantation, 2021, 27, 1704-1705.	1.3	0
52	Survival following simultaneous liver-lung versus liver alone transplantation: Results of the US national experience. American Journal of Surgery, 2021, 222, 813-818.	0.9	1
53	The Changing Burden of Alcoholic Hepatitis: Rising Incidence and Associations with Age, Gender, Race, and Geography. Digestive Diseases and Sciences, 2021, 66, 1707-1714.	1.1	9
54	Early Outcomes With the Liver-kidney Safety Net. Transplantation, 2021, 105, 1261-1272.	0.5	16

#	Article	IF	CITATIONS
55	Trends in deceased donor liver enzymes prior to transplant: The impact on graft selection and outcomes. American Journal of Transplantation, 2020, 20, 213-219.	2.6	12
56	Seroprevalence of HelicobacterÂpylori Infection in a National Cohort of Veterans With Noncardia Gastric Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2020, 18, 1235-1237.e1.	2.4	7
57	Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure. Hepatology, 2020, 72, 230-239.	3.6	35
58	Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. Gastroenterology, 2020, 158, 527-536.e7.	0.6	171
59	Risk prediction scores for acute on chronic liver failure development and mortality. Liver International, 2020, 40, 1159-1167.	1.9	22
60	Improvements in organ donation: Riding the coattails of a national tragedy. Clinical Transplantation, 2020, 34, e13755.	0.8	16
61	Addressing Critiques of the Proposed CMS Metric of Organ Procurement Organ Performance: More Data Isn't Better. Transplantation, 2020, 104, 1662-1667.	0.5	4
62	Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation, 2020, 104, 104-112.	0.5	14
63	Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation, 2020, 104, 476-481.	0.5	20
64	Wide Variation in the Percentage of Donation After Circulatory Death Donors Across Donor Service Areas: A Potential Target for Improvement. Transplantation, 2020, 104, 1668-1674.	0.5	12
65	The association of <i>Helicobacter pylori</i> with pancreatic cancer. GastroHep, 2020, 2, 157-164.	0.3	7
66	Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff?. Transplantation, 2020, 104, 2538-2546.	0.5	9
67	Screening Adult Children of Hepatitis C–Infected Baby Boomers: Barriers to Testing and Prevalence Estimates. Clinical Liver Disease, 2020, 16, 77-82.	1.0	1
68	Multicenter Study to Transplant Hepatitis C–Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 2678-2687	3.0	55
69	The impact of endoscopic submucosal dissection for gastric adenocarcinomas in the United States. Techniques and Innovations in Gastrointestinal Endoscopy, 2020, 22, 93-98.	0.4	0
70	Risk Factors and Centerâ€Level Variation in Hepatocellular Carcinoma Underâ€Staging for Liver Transplantation. Liver Transplantation, 2020, 26, 977-988.	1.3	13
71	Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2–positive donors. American Journal of Transplantation, 2020, 20, 1795-1799	2.6	53
72	Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Centerâ€Level Variability. Liver Transplantation, 2020, 26, 1052-1055.	1.3	37

#	Article	IF	CITATIONS
73	Models for acute on chronic liver failure development and mortality in a veterans affairs cohort. Hepatology International, 2020, 14, 587-596.	1.9	10
74	Oral Contraceptive–Induced Hepatic Sinusoidal Dilatation and Potential Implications for Living Donor Liver Transplantation: A Reason for Nonuse of Right Lobe Grafts. Liver Transplantation, 2020, 26, 722-725.	1.3	1
75	Rejecting bias: The case against race adjustment for OPO performance in communities of color. American Journal of Transplantation, 2020, 20, 2337-2342.	2.6	7
76	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	1.8	111
77	The proportion of Model for Endâ€stage Liver Disease Sodium score attributable to creatinine independently predicts postâ€transplant survival and renal complications. Clinical Transplantation, 2020, 34, e13817.	0.8	1
78	Response to: Deceased donors: Defining drugâ€related deaths. Clinical Transplantation, 2020, 34, e13828.	0.8	4
79	Oesophageal and proximal gastric adenocarcinomas are rare after detection of <i>Helicobacter pylori</i> infection. Alimentary Pharmacology and Therapeutics, 2020, 51, 781-788.	1.9	17
80	Rapid improvement in organ procurement organization performance: Potential for change and impact of new leadership. American Journal of Transplantation, 2020, 20, 3567-3573.	2.6	6
81	Immunosuppression in Donation After Circulatory Death Liver Transplantation: Can Induction Modify Graft Survival?. Liver Transplantation, 2020, 26, 1154-1166.	1.3	3
82	Associations of sociodemographic and clinical factors with gastrointestinal cancer risk assessment appointment completion. Journal of Genetic Counseling, 2020, 29, 616-624.	0.9	3
83	Transplanting Livers From "HCV-Positive―Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions. American Journal of Gastroenterology, 2020, 115, 1022-1023.	0.2	3
84	An opposing view to United States liver allocation problems with broader sharing. Current Opinion in Organ Transplantation, 2020, 25, 110-114.	0.8	10
85	Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception. Journal of the American College of Surgeons, 2020, 230, 503-512.e8.	0.2	1
86	US Organ Donation Policy. JAMA - Journal of the American Medical Association, 2020, 323, 279.	3.8	1
87	Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection. American Journal of Gastroenterology, 2020, 115, 716-722.	0.2	5
88	Yield and Implications of Pre-Procedural COVID-19 Polymerase Chain Reaction Testing on Routine Endoscopic Practice. Gastroenterology, 2020, 159, 1538-1540.	0.6	25
89	Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation. Hepatology, 2019, 69, 270-281.	3.6	36
90	Importance of incorporating standardized, verifiable, objective metrics of organ procurement organization performance into discussions about organ allocation. American Journal of Transplantation, 2019, 19, 2973-2978.	2.6	39

#	Article	IF	CITATIONS
91	Ruralâ€Urban Differences in Inâ€Hospital Mortality Among Admissions for Endâ€Stage Liver Disease in the United States. Liver Transplantation, 2019, 25, 1321-1332.	1.3	10
92	Use of public health service increased risk kidneys in pediatric renal transplant recipients. Pediatric Transplantation, 2019, 23, e13405.	0.5	2
93	Reply:. Hepatology, 2019, 70, 2236-2238.	3.6	4
94	The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes. American Journal of Transplantation, 2019, 19, 3319-3327.	2.6	24
95	Declining predictive performance of the MELD: Cause for concern or reflection of changes in clinical practice?. American Journal of Transplantation, 2019, 19, 3221-3222.	2.6	2
96	Reducing Hospital Admissions for Paracentesis: A Quality Improvement Intervention. Clinical Gastroenterology and Hepatology, 2019, 17, 2630-2633.e2.	2.4	10
97	Preâ€ŧransplant alphaâ€fetoprotein is associated with postâ€ŧransplant hepatocellular carcinoma recurrence mortality. Clinical Transplantation, 2019, 33, e13634.	0.8	19
98	Inâ€Hospital mortality varies by procedure type among cirrhosis surgery admissions. Liver International, 2019, 39, 1394-1399.	1.9	17
99	Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ. American Journal of Transplantation, 2019, 19, 2525-2532.	2.6	11
100	Outcomes of Living-donor Liver Transplantation Using Grafts Heterozygous for α-1 Antitrypsin Gene Mutations. Transplantation, 2019, 103, 1175-1180.	0.5	8
101	Characterization of early hepatic injury in HCVâ€negative recipients of HCVâ€infected kidneys. Clinical Transplantation, 2019, 33, e13494.	0.8	4
102	Donation After Circulatory Death Liver Procurement: Time to Consider More Options?. Liver Transplantation, 2019, 25, 533-534.	1.3	2
103	Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single-arm trial. American Journal of Transplantation, 2019, 19, 2533-2542.	2.6	88
104	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Doubleâ€Blind, Placebo ontrolled Trial. Liver Transplantation, 2019, 25, 1155-1164.	1.3	26
105	National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. Journal of the American Society of Nephrology: JASN, 2019, 30, 1939-1951.	3.0	67
106	Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus–Viremic Livers. Liver Transplantation, 2019, 25, 1800-1810.	1.3	4
107	Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virusâ€infected donors into hepatitis C virusâ€negative patients. Seminars in Dialysis, 2019, 32, 179-186.	0.7	6
108	Incidence and Mortality of Acuteâ€onâ€Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology, 2019, 69, 2150-2163.	3.6	139

#	Article	IF	CITATIONS
109	Early Liver Transplantation for Alcoholic Hepatitis. Gastroenterology, 2019, 156, 284-285.	0.6	6
110	Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease. Liver Transplantation, 2019, 25, 388-398.	1.3	11
111	Transplanting livers from HCV â€infected donors into HCV â€negative recipients: Promise but mind the pitfalls. American Journal of Transplantation, 2019, 19, 1264-1265.	2.6	2
112	Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus–Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. American Journal of Kidney Diseases, 2019, 73, 815-826.	2.1	27
113	Variability in acceptance of organ offers by pediatric transplant centers and its impact on waitâ€ŀist mortality. Liver Transplantation, 2018, 24, 803-809.	1.3	19
114	Exploring opportunities to prevent cirrhosis admissions in the emergency department: A multicenter multidisciplinary survey. Hepatology Communications, 2018, 2, 237-244.	2.0	9
115	Liver paired exchange: Can the liver emulate the kidney?. Liver Transplantation, 2018, 24, 677-686.	1.3	23
116	Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation, 2018, 102, e163-e170.	0.5	35
117	Important Facts About Organ Donation and OPO Performance. Transplantation, 2018, 102, e249-e250.	0.5	8
118	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology and Hepatology, 2018, 16, 591-593.	2.4	20
119	Indeterminate QuantiFERON-TB Cold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflammatory Bowel Diseases, 2018, 24, 217-226.	0.9	9
120	Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 617-625.	1.8	59
121	Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. Annals of Surgery, 2018, 267, 922-928.	2.1	34
122	Incidence, determinants and outcomes of pregnancyâ€associated hepatitis B flares: A regional hospitalâ€based cohortÂstudy. Liver International, 2018, 38, 813-820.	1.9	34
123	Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?. Liver Transplantation, 2018, 24, 12-14.	1.3	9
124	Hepatitis C virus genotyping of organ donor samples to aid in transplantation of <scp>HCV</scp> â€positive organs. Clinical Transplantation, 2018, 32, e13172.	0.8	9
125	Functional status, healthcare utilization, and the costs of liver transplantation. American Journal of Transplantation, 2018, 18, 1187-1196.	2.6	34
126	Quantifying the Effect of Transplanting Older Donor Livers Into Younger Recipients: The Need for Donor-recipient Age Matching. Transplantation, 2018, 102, 2033-2037.	0.5	24

#	Article	IF	CITATIONS
127	Hepatic Dysfunction in Deceased Donors in the Age of the Opioid Epidemic. Transplantation, 2018, 102, e403-e403.	0.5	4
128	Analysis of the Nature and Frequency of Domestic Transplant Tourism in the United States. Liver Transplantation, 2018, 24, 1762-1764.	1.3	6
129	Is the Pediatric End-stage Liver Disease Score Truly a Detriment to Pediatric Liver Allocation?. JAMA Pediatrics, 2018, 172, 1013.	3.3	2
130	Maximizing utilization of the donor pool by appropriate classification of hepatitis C antibody–positive donors. American Journal of Transplantation, 2018, 18, 2380-2381.	2.6	4
131	Twelve-Month Outcomes After Transplant of Hepatitis C–Infected Kidneys Into Uninfected Recipients. Annals of Internal Medicine, 2018, 169, 273-281.	2.0	193
132	New Insights Into Optimal Timing of Hepatitis C Virus Treatment for Dialysis Patients Waitlisted for Kidney Transplant. Annals of Internal Medicine, 2018, 169, 256.	2.0	3
133	Transplantation in foreign nationals: Lower rates of waitlist mortality and higher rates of lost to follow-up posttransplant. American Journal of Transplantation, 2018, 18, 2663-2669.	2.6	11
134	Reply to: "Is obesity a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis?― Journal of Hepatology, 2018, 69, 758.	1.8	0
135	Hepatitis C Virus-Viremic Liver Transplantation. Gastroenterology and Hepatology, 2018, 14, 590-592.	0.2	0
136	Lactulose Is Associated With Decreased Risk of Clostridium difficile Infection in Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 2017, 15, 953-954.	2.4	15
137	Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology, 2017, 152, 1090-1099.e1.	0.6	487
138	Allocating Organs to Cognitively Impaired Patients. New England Journal of Medicine, 2017, 376, 299-301.	13.9	14
139	Increased Distance to a Liver Transplant Center Is Associated With Higher Mortality for Patients With Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2017, 15, 958-960.	2.4	25
140	Exception Points and Body Size Contribute to Gender Disparity in Liver Transplantation. Clinical Gastroenterology and Hepatology, 2017, 15, 1286-1293.e2.	2.4	56
141	Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Current Hepatology Reports, 2017, 16, 12-17.	0.4	13
142	Early Detection of Hepatocellular Carcinoma After Treatment With Direct-Acting Antivirals: Selection Bias or Biologically Plausible?. Gastroenterology, 2017, 152, 2072-2075.	0.6	3
143	Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. New England Journal of Medicine, 2017, 376, 2394-2395.	13.9	315
144	Interpreting Outcomes in DCDD Liver Transplantation. Transplantation, 2017, 101, 1067-1073.	0.5	40

#	Article	IF	CITATIONS
145	Share 35 changes in centerâ€level liver acceptance practices. Liver Transplantation, 2017, 23, 604-613.	1.3	30
146	Financial impact of share 35: Encouraging early results but many unanswered questions. Liver Transplantation, 2017, 23, 9-10.	1.3	0
147	Acute Rejection Increases Risk of Graft Failure and Death inÂRecent Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2017, 15, 584-593.e2.	2.4	162
148	Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology, 2017, 65, 864-874.	3.6	94
149	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. Open Forum Infectious Diseases, 2017, 4, ofx012.	0.4	6
150	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Medicine, 2016, 13, e1002007.	3.9	55
151	Recurrent primary sclerosing cholangitis in the Adultâ€ŧoâ€Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients. Liver Transplantation, 2016, 22, 1214-1222.	1.3	51
152	Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiology and Drug Safety, 2016, 25, 628-636.	0.9	35
153	Pretransplant echocardiographic parameters as markers of posttransplant outcomes in liver transplant recipients. Liver Transplantation, 2016, 22, 316-323.	1.3	41
154	Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1638-1646.e2.	2.4	30
155	Reply to "Revising metrics for aggressiveness assessment in liver transplantation centers― Journal of Hepatology, 2016, 65, 1067-1068.	1.8	0
156	Comparing American Gastroenterological Association Pancreatic Cyst Management Guidelines with Fukuoka Consensus Guidelines as Predictors of Advanced Neoplasia in Patients with Suspected Pancreatic Cystic Neoplasms. Journal of the American College of Surgeons, 2016, 223, 729-737e1.	0.2	40
157	The Role of Obeticholic Acid in Gut Bacterial Translocation and Inflammation. Gastroenterology, 2016, 151, 759-761.	0.6	6
158	Defining disparities in liver transplantation: The devil is in the details. Liver Transplantation, 2016, 22, 1720-1723.	1.3	3
159	Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records database. Pharmacoepidemiology and Drug Safety, 2016, 25, 405-412.	0.9	4
160	Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. Journal of Clinical Gastroenterology, 2016, 50, 258-265.	1.1	38
161	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 918-919.	2.4	1
162	Reply to "ls the post-transplant survival the unique Holy Grail?― Journal of Hepatology, 2016, 64, 523-524.	1.8	1

#	Article	IF	CITATIONS
163	Liver transplant center variability in accepting organ offers and its impact on patient survival. Journal of Hepatology, 2016, 64, 843-851.	1.8	62
164	Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. Gastroenterology, 2016, 151, 120-129.e5.	0.6	145
165	Impact of Anticoagulation on Upper Gastrointestinal Bleeding in Cirrhosis. Gastroenterology, 2016, 150, 1239-1241.	0.6	2
166	Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit. Gastroenterology, 2016, 150, 306-309.	0.6	8
167	Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. American Journal of Medicine, 2016, 129, 283-291.e5.	0.6	65
168	Eliminating transplant tourism in the United States as a means to decrease waitâ€list mortality of US residents. Liver Transplantation, 2015, 21, 1112-1113.	1.3	2
169	Racial and ethnic disparities in access to and utilization of living donor liver transplants. Liver Transplantation, 2015, 21, 904-913.	1.3	37
170	Liver transplant readmissions: The cost of the revolving door. Liver Transplantation, 2015, 21, 868-869.	1.3	5
171	Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiology and Drug Safety, 2015, 24, 676-683.	0.9	17
172	The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model. Clinical Gastroenterology and Hepatology, 2015, 13, 302-309.e11.	2.4	35
173	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. Clinical Gastroenterology and Hepatology, 2015, 13, 2360-2368.	2.4	57
174	Early post-transplant survival: Interaction of MELD score and hospitalization status. Journal of Hepatology, 2015, 63, 601-608.	1.8	38
175	The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 2118-2127.	2.4	30
176	Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 303-307.	1.1	15
177	Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System. Gastroenterology, 2015, 148, 1353-1361.e3.	0.6	90
178	Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. Clinical Infectious Diseases, 2015, 61, 1054-1062.	2.9	28
179	Standardizing MELD Exceptions: Current Challenges and Future Directions. Current Transplantation Reports, 2014, 1, 232-237.	0.9	37
180	Association of Distance From a Transplant Center With Access to Waitlist Placement, Receipt of Liver Transplantation, and Survival Among US Veterans. JAMA - Journal of the American Medical Association, 2014, 311, 1234.	3.8	127

#	Article	IF	CITATIONS
181	Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Hepatology, 2014, 60, 1717-1726.	3.6	54
182	Liver Transplants Among US Veterans—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 437.	3.8	1
183	Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database. Gastroenterology, 2014, 146, 1256-1265.e1.	0.6	105
184	Reframing the impact of combined heart-liver allocation on liver transplant wait-list candidates. Liver Transplantation, 2014, 20, 1356-1364.	1.3	18
185	End-organ consequences of the Fontan operation: liver fibrosis, protein-losing enteropathy and plastic bronchitis. Cardiology in the Young, 2013, 23, 831-840.	0.4	79
186	Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini‧entinel Distributed Database. Pharmacoepidemiology and Drug Safety, 2013, 22, 861-872.	0.9	46
187	Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transplantation, 2013, 19, 250-258.	1.3	46
188	Center variation in the use of nonstandardized model for end-stage liver disease exception points. Liver Transplantation, 2013, 19, 1330-1342.	1.3	30
189	Underreporting of Liver Transplant Waitlist Removals Due to Death or Clinical Deterioration. Transplantation, 2013, 96, 211-216.	0.5	42
190	Deceased Organ Donation Consent Rates Among Racial and Ethnic Minorities and Older Potential Donors*. Critical Care Medicine, 2013, 41, 496-505.	0.4	84
191	Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transplantation, 2012, 18, 434-443.	1.3	121
192	Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transplantation, 2011, 17, 1355-1363.	1.3	54
193	Intramural Dissection of the Esophagus in a Young Man Presenting With Hematemesis. Clinical Gastroenterology and Hepatology, 2010, 8, A18.	2.4	0
194	Worth a Second Look. American Journal of Medicine, 2009, 122, 24-26.	0.6	14
195	Screening for Celiac Disease in Family Members: Is Follow-up Testing Necessary?. Digestive Diseases and Sciences, 2007, 52, 1082-1086.	1.1	28